$ALGN

Align Technology said it awarded 12 dentistry research grants to universities worldwide under its Fifteenth Annual Research Award Program. The company said an independent academic committee first reviewed applications, with Align selecting recipients. Topics include Invisalign-related clinical studies and device evaluations. Align also described its Invisalign, iTero, and exocad offerings and its scale of doctor customers and treated patients.

Align Technology, Inc. (ALGN) disclosed an Amendment No. 1 to a Schedule 13G filed by Gund-related holders. The reporting persons, including G. Zachary Gund and Grant Gund, beneficially own 3,812,981 shares, or 5.4% of ALGN common stock, based on 71,039,852 shares outstanding as of July 31, 2026.

Align Technology said a Jinan Intermediate People’s Court issued a first-instance ruling on Aug. 10, 2026 in a China patent case against Angel. The court found Angel’s MasterForce and ATreat systems infringe Align’s CN113693748B patent and ordered Angel to stop use, manufacturing, and sales, awarding RMB 10 million in damages. Angel can appeal to China’s Supreme People’s Court.

Align Technology (Nasdaq: ALGN) said China’s Jinan Intermediate People’s Court ruled in its favor in a patent infringement case against Angelalign’s China subsidiaries. The court found Angel infringed Align’s CN113693748B patent tied to extraction-gap-closure technology, ordering a stop to use and sales in China and awarding RMB 10 million in damages. Angel can appeal.

3D Systems reported Q2 revenue of $94.6M, flat YoY, with healthcare up 6.8% and aerospace/defense and data center infrastructure each growing over 20%. Adjusted EBITDA loss narrowed to $0.8M. It expects Q3 revenue of $96M to $99M. Prodways posted Q2 revenue of €10.5M (+5% YoY) and plans a €20M buyback. Align Technology reported record Q2 revenue of just over $1.05B (+4.3%), with clear aligner revenue up 8.2% and 2026 revenue growth guidance of 3% to 4%.

Align Technology (ALGN) reported Q2 2026 sales of $1,056.19 million year over year and issued softer sequential Q3 revenue guidance, citing one-time restructuring, depreciation, and legal charges affecting its GAAP operating margin outlook. After talks with Elliott Investment Management, it plans to appoint three independent directors and raised its 2026 buyback to $400 million to $500 million.

Align Technology (ALGN) reported Q2 2026 revenue of $1,056.2 million, up 4.3% y/y, driven by record Clear Aligner volumes and higher ASPs. Clear Aligner revenue rose 8.2% to $870.9 million on 691,785 cases. Systems and Services revenue fell 10.8% to $185.3 million. Q3 revenue guidance is $1.00 to $1.02 billion; full-year growth 3% to 4%.

Align Technology said it will open a new manufacturing facility in Hyderabad, India, in 2027, its first in India. The company plans to create more than 300 direct jobs and spend about $200 million in capital and operational expenses over several years. Align expects the facility to be margin accretive in its first year, citing supply-chain resilience and growth in India.

Align Technology reported Q2 revenue of $1.06B vs $1.05B expected and adjusted EPS of $2.64 vs $2.60. Adjusted operating income was $241.7M. Sales volumes rose 7.4% YoY, but Q3 CY2026 revenue guidance midpoint was $1.01B vs $1.02B estimates. Margin fell to 14.6%.

Align Technology (ALGN) reported Q2 results and issued new Q3 and full-year 2026 guidance on July 29, alongside a buyback update. The guidance points to softer Q3 revenue and one-time restructuring charges, with sentiment mixed. The article cites a fair value of $209.07 versus a $172.89 close and discusses risks from EU antitrust outcomes and weaker scanner demand.